Clinical Application of A New In Vitro High-throughput Drug Sensitivity Screening Technology in Individualized Medication of Relapsed Refractory Acute Myeloid Leukemia Patients
Objective To explore the clinical value of new high-throughput drug sensitivity (HDS) screening technology in the individualized medication of relapsed refractory acute myeloid leukemia patients. Methods We collected bone marrow samples of 19 patients with relapsed and refractory acute myeloid leuke...
Main Authors: | WU Haibing, ZHAO Xiaoyan, SHEN Mingfang, Huang Rui, CHEN Cheng, REN Tao, SHEN Yang |
---|---|
Format: | Article |
Language: | zho |
Published: |
Magazine House of Cancer Research on Prevention and Treatment
2020-06-01
|
Series: | Zhongliu Fangzhi Yanjiu |
Subjects: | |
Online Access: | http://html.rhhz.net/ZLFZYJ/html/8578.2020.19.1364.htm |
Similar Items
-
Feasibility of high-throughput drug sensitivity screening (HDS)-guided treatment for children with refractory or relapsed acute myeloid leukemia
by: Wenxiu Lv, et al.
Published: (2023-02-01) -
Timed Sequential Salvage Chemotherapy for Relapsed or Refractory Acute Myeloid Leukemia
by: Bogdan Popescu, et al.
Published: (2019-12-01) -
B Cell Deficiency in Patients with Relapsed and Refractory Acute Myeloid Leukemia
by: Meghali Goswami, et al.
Published: (2020-07-01) -
A review of treatment options employed in relapsed/refractory AML
by: Mohamed Zakee Mohamed Jiffry, et al.
Published: (2023-12-01) -
Efficacy and toxicity of CLAG combined with pegylated liposomal doxorubicin in the treatment of refractory or relapsed acute myeloid leukemia
by: Han Yao, et al.
Published: (2023-06-01)